Botox Chart Note Template for Med Spa Injectors

You have twelve patients today. The last one leaves at 6:40. The chart for the 2:15 tox visit says "Botox, glabella and crows, 44 units, tolerated well." That is not a bad note. It is also not a note you want read aloud in a board hearing or a malpractice deposition.

A neurotoxin note has one job. Six months from now, a different injector, a medical director, or an investigator should open it and know exactly what happened. They need to see which vial you used, where you injected, and who authorized the order. Here is what that note contains, a template you can paste into your EMR, and one worked example.

What goes into a defensible neurotoxin note?

A defensible note covers five layers of detail.

• Who: patient identifiers, injector name and credentials, supervising or ordering physician, NP, or PA.

• Why: the indication and the areas treated, plus a reference to the good faith exam that authorized treatment and its date.

• With what: product name, lot number, expiration date, reconstitution volume and resulting concentration.

• How: total units, units per site with a face-map reference, needle gauge, injection depth and technique.

• What happened after: adverse events or "none," aftercare given, follow-up plan, photos taken or declined.

Consent belongs in the chart too. Keep it as a signed document on file with the date, not as a checkbox. AmSpa's article "What You Need to Know About Patient Charting" names missing informed consent documentation as the single most common shortfall it sees.

Fill-in neurotoxin chart note template

Copy this block into your EMR's tox note template. Fill every line. If a line does not apply, write "N/A," because a blank reads as forgotten.

• Patient name, DOB, chart ID:

• Date and time of service:

• Consent on file: signed neurotoxin consent dated ____ (verified today: Y/N)

• Good faith exam: performed by ____ (credential) on ____; no change in history or condition since

• Patient-specific order or treatment plan dated ____ by ____

• Indication and areas treated:

• Allergies and relevant history reviewed today (pregnancy, neuromuscular disease, prior tox response):

• Product name and manufacturer:

• Lot number: ____ Expiration: ____

• Reconstitution: ____ mL preservative-free saline per ____ unit vial = ____ units per 0.1 mL; reconstituted on ____ at ____

• Total units administered:

• Units per site, referenced to face map ____ (attach or reference diagram):

• Needle gauge, depth, technique:

• Pre-injection skin prep:

• Immediate response and adverse events (or "none observed"):

• Aftercare instructions given (verbal and written):

• Follow-up plan:

• Photos: pre-treatment taken Y/N; if declined, note patient declined

• Injector name, credentials, signature, time:

• Supervising physician, NP, or PA name:

Example of a completed Botox chart note

Everything below is fictional, including the patient, the lot number, and the staff.

• Patient: J. Reyes, DOB 04/12/1985, chart 10442

• Date and time of service: 09/17/2026, 2:15 pm

• Consent on file: signed neurotoxin consent dated 03/02/2026, verified today, no changes

• Good faith exam: performed by Dr. A. Chen, MD, on 03/02/2026 (in person); no change in history or condition since

• Patient-specific order dated 03/02/2026 by Dr. A. Chen: onabotulinumtoxinA to glabella and lateral canthal lines, up to 50 units per visit, interval no less than 12 weeks

• Indication and areas treated: moderate to severe glabellar lines and lateral canthal lines

• History reviewed: not pregnant, no neuromuscular disease, no aminoglycoside use, prior tox 03/02/2026 without adverse event

• Product: Botox Cosmetic (onabotulinumtoxinA), AbbVie

• Lot number: C7Q31XZ (fictional) Expiration: 02/2027

• Reconstitution: 2.5 mL preservative-free 0.9% saline per 100 unit vial = 4 units per 0.1 mL; reconstituted 09/17/2026 at 1:50 pm

• Total units administered: 44

• Units per site (face map A on file): glabella 20 units at 5 sites, 4 units each (2 per corrugator, 1 procerus); lateral canthal lines 24 units at 6 sites, 4 units each (3 per side)

• Needle and technique: 31g 0.5 inch, intramuscular, perpendicular, 0.1 mL per site

• Skin prep: alcohol, allowed to dry

• Immediate response: mild erythema at injection points, no bleeding, no vasovagal response; adverse events: none observed

• Aftercare: remain upright 4 hours, no rubbing or pressure on treated areas today, no strenuous exercise today; written sheet given

• Follow-up: 2 week touch-up check offered; next full treatment no sooner than 12 weeks

• Photos: pre-treatment frontal and bilateral oblique taken and stored

• Injector: M. Okafor, RN, signed 2:38 pm

• Supervising physician: A. Chen, MD

The reconstitution and dosing figures above match the Botox Cosmetic prescribing information. That label lists 2.5 mL of diluent per 100 unit vial to yield 4 units per 0.1 mL, 20 units at 5 sites for glabellar lines, and 24 units at 6 sites for lateral canthal lines. The same labeling says reconstituted product should be refrigerated and used within 24 hours. Your practice may use a different dilution. Write it down every time.

What are the most common charting mistakes in med spas?

Missing consent documentation, thin supporting documentation, and no record of supervision are the three gaps AmSpa names most often.

AmSpa's charting article lists them this way: informed consent that was never documented, supporting documentation that does not back up the treatment given, and no record of supervision when a delegated treatment was performed. We have not audited anyone's notes, so treat these as the compliance educators' list, not ours.

In the injectables world, those three show up in a specific way.

• Consent: a signed form exists somewhere, but the note never references its date or confirms it was reviewed today.

• Supporting documentation: "44 units" with no lot number, no dilution, and no per-site breakdown, so the treatment cannot be reproduced or traced in a recall.

• Supervision: no ordering provider named, no good faith exam date, so the note cannot show the injector was acting under a valid order.

One habit fixes all three. Never sign a tox note without a lot number, a units-per-site line, and the ordering provider's name.

How does Symbal help with neurotoxin charting?

Symbal listens to the visit and writes a structured chart note for your EMR.

We built Symbal to capture the visit as it happens. The injector taps record and talks through the visit normally: "four units at each of the five glabellar points, lot ending in XZ." Symbal writes a structured note with those details in the right fields. You review and approve every note. A Chrome extension fills the fields in Boulevard, Aesthetic Record, or PatientNow.

Frequently asked questions

Do I need a face diagram?

No law we are aware of requires a diagram, but a units-per-site record referenced to a labeled map is the clearest way to show where product went. Many EMRs include a face map you can mark. If yours does not, a numbered site list ("site 3, right corrugator, 4 units") does the same job.

How long do I have to keep neurotoxin records?

Retention rules depend on your state. A summary of state rules published by Paubox lists California at seven years or more for adults, New York at six, and Florida physicians at five, and notes that many states cluster around seven years. Confirm with your state medical board and your medical director. Keep records for minors longer.

What if the patient declines photos?

Chart that the patient declined and note that you explained the risk of having no baseline. Photos help in asymmetry and ptosis disputes. Your written per-site record still has to stand on its own.

Documentation is the part of the visit nobody gets paid for and everybody gets judged on. Try Symbal free for 7 days, no credit card required.